Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0C0ME
|
||||
Former ID |
DPR000099
|
||||
Drug Name |
RO-26-2853
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Preclinical | [536447] | ||
Company |
Roche
|
||||
Target and Pathway | |||||
Target(s) | 72 kDa type IV collagenase | Target Info | Inhibitor | [536447] | |
PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
Pathway Interaction Database | LPA receptor mediated events | ||||
Plasma membrane estrogen receptor signaling | |||||
Osteopontin-mediated events | |||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
Direct p53 effectors | |||||
amb2 Integrin signaling | |||||
ATF-2 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Regulation of nuclear beta catenin signaling and target gene transcription | |||||
Syndecan-2-mediated signaling events | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.